Research programme: serotonin 2A receptor inverse agonists - Arena Pharmaceuticals

Drug Profile

Research programme: serotonin 2A receptor inverse agonists - Arena Pharmaceuticals

Alternative Names: AR 116081; AR 116082

Latest Information Update: 21 Apr 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arena Pharmaceuticals
  • Developer Arena Pharmaceuticals; Tripos
  • Class Small molecules
  • Mechanism of Action Serotonin 2A receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Schizophrenia; Sleep disorders

Most Recent Events

  • 10 Apr 2008 Pharmacodynamics data presented at the 235th American Chemical Society National Meeting (235th-ACS-2008)
  • 20 Jul 2007 APD 791 has entered clinical development
  • 22 Feb 2006 Preclinical trials in Acute coronary syndromes in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top